Oppenheimer Asset Management Inc. Raises Position in Haleon plc (NYSE:HLN)

Oppenheimer Asset Management Inc. boosted its holdings in Haleon plc (NYSE:HLN) by 14.4% during the first quarter, Holdings Channel.com reports. The firm owned 696,388 shares of the company’s stock after acquiring an additional 87,781 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Haleon were worth $5,912,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in HLN. Hexagon Capital Partners LLC grew its position in Haleon by 107.3% in the 4th quarter. Hexagon Capital Partners LLC now owns 4,236 shares of the company’s stock worth $35,000 after purchasing an additional 2,193 shares during the period. Pinnacle Bancorp Inc. raised its position in shares of Haleon by 853.4% during the fourth quarter. Pinnacle Bancorp Inc. now owns 4,767 shares of the company’s stock valued at $39,000 after buying an additional 4,267 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in shares of Haleon during the 1st quarter valued at about $43,000. Tower Research Capital LLC TRC boosted its stake in Haleon by 146.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,398 shares of the company’s stock valued at $44,000 after buying an additional 3,211 shares during the last quarter. Finally, SRS Capital Advisors Inc. grew its holdings in shares of Haleon by 456.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 5,458 shares of the company’s stock valued at $45,000 after purchasing an additional 4,477 shares in the last quarter. Institutional investors own 6.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on HLN. Argus restated a “buy” rating on shares of Haleon in a report on Tuesday, March 26th. Berenberg Bank started coverage on Haleon in a report on Wednesday, June 5th. They issued a “buy” rating for the company. Finally, HSBC assumed coverage on Haleon in a report on Wednesday, April 17th. They set a “buy” rating for the company. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy”.

Haleon Stock Performance

NYSE:HLN traded up $0.10 during trading hours on Friday, reaching $8.90. The company had a trading volume of 2,482,788 shares, compared to its average volume of 3,186,633. The firm has a market cap of $40.64 billion, a PE ratio of 29.67, a price-to-earnings-growth ratio of 2.55 and a beta of 0.24. Haleon plc has a 1-year low of $7.70 and a 1-year high of $8.96. The business’s 50 day moving average price is $8.45 and its 200-day moving average price is $8.37. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.04 and a quick ratio of 0.73.

Haleon (NYSE:HLN) last announced its earnings results on Wednesday, May 1st. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.01. Haleon had a return on equity of 13.17% and a net margin of 9.68%. The firm had revenue of $3.70 billion for the quarter, compared to analyst estimates of $3.71 billion. Research analysts forecast that Haleon plc will post 0.46 EPS for the current year.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.